You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Using Automated Abstractions to Classify System States for Software Health Monitoring
SBC: ARIES DESIGN AUTOMATION, LLC Topic: 9040477In most critical software systems, a state that is partially visible through values passed across interfaces contains information that could determine the health of the software system, and whether a failure is likely in the future. Some of this information behaves in a continuous fashion, e.g., the available memory or disk space is easily interpreted to monitor system health. Other values are nom ...
SBIR Phase I 2011 Department of CommerceNational Institute of Standards and Technology -
A Versatile Microbot Fabrication Platform
SBC: AMT Nano, LLC Topic: 9050768RAMT Nano, LLC has developed innovative technology for achieving a versatile microrobot platform. The innovation relies on a unique micromolding process, which is low-cost and high-throughput, and high precison. The process achieves versatility by generating deterministic freeform shapes in polymers and nanocomposites. Several perceived benefits accompany the micromolding process. Due to the three- ...
SBIR Phase I 2011 Department of CommerceNational Institute of Standards and Technology -
Development of a Scalable, Low-Cost, Ultrananocrystalline Diamond Electrochemical Process for the Destruction of Contaminants of Emerging Concern (CECs)
SBC: Advanced Diamond TechNologies, Inc. Topic: EThis Small Business Innovation Research (SBIR) project will develop and ready for commercialization a scalable, low-cost process for purification of water containing Contaminants of Emerging Concern (CECs) using anodic oxidation with boron-doped ultrananocrystalline diamond (UNCD®) thin films. Resent research demonstrated that there is considerable potential for the development of electrochemica ...
SBIR Phase I 2011 Environmental Protection Agency -
L-(+) Lactic Acid Production from Biodiesel Waste Using Pelletized Fungal Fermentation
SBC: OMNILANE INC Topic: H"With the rapid growth of biodiesel industry, the production of crude glycerol as one of major biodiesel byproducts has been dramatically increased. Fully utilizing such a large quantity of crude glycerol is critical to the sustainability of biodiesel industry. Lactic acid is an important industrial chemical that is widely used as a food additive for flavoring and preservative, a moistener in co ...
SBIR Phase I 2011 Environmental Protection Agency -
FEMOVAL OF GASOLINE FROM WATE SUPPLIES
SBC: Lowry Engineering Inc. Topic: N/ATHE FEASIBILITY OF AMULTI-STAGED DIFFUSED AERATION TREATMENTSYSTEM FOR GASOLINE REMOVAL FROM CONTAMINATED HOUSEHOLD GROUND WATER SUPPLIES WILL BE STUDIED. EXPERIMENTS IN THE LABORATORY AND FIELD WILL IDENTIFY THE CONTROLLING GASOLINE COMPONENT COMPOUNDS FOR THE SYSTEM. THESE ADDITIVES ARE LIKELY TO INCLUDE METHYL TERTIARY BUTYL ETHER (MTBE) AND OTHER HIGHLY SOLUBLE AND POORLY ADSORBED COMPOUNDS. E ...
SBIR Phase I 1986 Environmental Protection Agency -
A transfollicular nanovaccine against leishmaniasis
SBC: VINDICO NANOBIOTECHNOLOGY, INC. Topic: NIAIDDESCRIPTION (provided by applicant): The World Health Organization estimates that over 350 million people are at risk of developing leishmaniasis and infection prevalence is 14 million people in the world. Annually, 2 million people are infected with Leishmania species and 270,000 will die. Leishmaniasis is one of the most important parasitic diseases affecting the U.S. military today, with over 2 ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Rapid Response Vaccines for Botulinum Neurotoxins
SBC: Iterative Therapeutics Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most potent protein toxins known. Given their potent toxicity and their potential use in bio-warfare scenarios, BoNTs are included among the Category A select agents. The currentlyavailable pentavalent toxoid vaccine requires multiple boosters before being effective, and protects unequally against the different BoNT serotyp ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Apparatus and Method for Convection Enhanced Therapeutic Delivery
SBC: FHC, INC. Topic: NCIDESCRIPTION (provided by applicant): Malignancies of the brain are among the most devastating diseases known. Glioblastoma multiform (GBM) in particular are known for their rapid, uncontrolled, and aggressive growth. Very little progress has been made in the treatment of GBM over the past 25 years. A more recent promising therapeutic approach is convection enhanced delivery (CED) in which chemothe ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Modulation of In Vivo Tumor Oxygenation via Polymersome-encapsulated Myoglobin
SBC: VINDICO NANOBIOTECHNOLOGY, INC. Topic: NCIDESCRIPTION (provided by applicant): Over 250,000 new cases of head and neck cancers (HNCs) and non-small cell lung cancers (NSCLCs) are diagnosed every year in the United States. At the time of diagnosis, 60% of these cases are regionally advanced (stageIII and IV). Wide surgical excision is not the immediate therapeutic option for most of these locally advanced solid tumor malignancies. A number ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Multifunctional Peptides for (MRI) Imaging
SBC: CDG THERAPEUTICS, INC. Topic: NCIDESCRIPTION (provided by applicant): Our overall goal is to expand the role of CPPs in molecular imaging at the patient level using large animal models of human tumors and a peptide agent that inherently provides 1) preferential access to a wide variety ofhuman solid (and hematologic) tumor cells, 2) an increased intracellular concentration (2-12 fold) over histologically matched normal cells, and ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health